Then, just a few days after receiving permission to start final-stage trials for a SARS-CoV-2 vaccine, one of India’s largest generic pharma companies reportedly suffered a cyber-attack and had to shut down plants in a few countries. In July 2020, the US Justice Department alleged that foreign nationals were finding ways to penetrate the networks of biotech and other firms that are known to be working on vaccines, treatments, and testing technology in at least 11 countries, including the US. Multinational professional services organization PriceWaterhouseCoopers (PwC) has identified IP theft threats and disruption at both the research and trials stages, as well as manufacturing disruptions. They can destabilize the SARS-CoV-2 vaccine development and supply chain using a variety of techniques. Nation-state actors are patient, persistent, well-funded and sophisticated. Players in the highly intertwined network of big pharma, biotech, contract development and manufacturing organizations (CDMOs), and health and clinical research institutions are all at risk. Potential targets include those in the business of researching, developing, conducting trials, manufacturing, or distributing the SARS-CoV-2 vaccine. ![]() Additionally, the enormously valuable intellectual property and data on the vaccines, components and therapeutics are relatively easy for threat actors to take.In fact, nation-states are already attempting to steal vaccine formulae and disrupt operations. Any such return can be critically aided by an adequate supply of vaccines which can be administered to millions of people without a hitch.However, the SARS-CoV-2 vaccine supply chain – which tackles the COVID-19 disease – is rife with logistical complexities. ![]() In the wake of the pandemic, nations worldwide are seeking a return to good public health and economic recovery.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |